Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,243 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasting Clear all

Conditions: Non Small Cell Lung Cancer
Interventions: Capmatinib, Nazartinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: TAK-831; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteer
Interventions: BIIB091; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Environmental Enteric Dysfunction
Interventions: TNIB Catheter; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Dexpramipexole; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: PreDiabetes
Interventions: Ad libitum meal timing, Twice a day meals; Other
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 30 Years to 70 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Healthy Adults
Interventions: Crucera-SGS, Meriva 500-SF; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Weight Loss
Interventions: Weight Loss Phase, HP-IF, HH; Behavioral
Lead sponsor: Skidmore College; Other
Eligibility: 30 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Saratoga Springs, New York

Conditions: Intermittent Fasting, Aging
Interventions: Time restricted eating; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 55 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Schizophrenia
Interventions: ASP6981, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Austin, Texas

Conditions: Cigarette Smoking
Interventions: refresh; Behavioral
Lead sponsor: Pro-Change Behavior Systems; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: South Kingstown, Rhode Island

Conditions: Food Effect of Tivozanib in Health Subjects
Interventions: tivozanib; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: 1: Liothyronine Sodium Tablets, 2: Cytomel® Tablets; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hyperphosphatemia, Chronic Kidney Disease
Interventions: K2CG chewing gum; Other
Lead sponsor: Denver Nephrologists, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Healthy Volunteers
Interventions: Treatment A - 400 mg Fasting, Treatment B - 400 mg Fed, Treatment C - 200 mg Fed; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Cardiovascular Diseases
Interventions: Oatmeal; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Familial Chylomicronemia Syndrome (FCS)
Interventions: LCQ908, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seatlle, Washington

Conditions: Healthy Volunteer Study
Interventions: Fixed-Dose Combination (FDC) Tablet; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy
Interventions: Zaleplon 10 mg Capsules, SONATA® 10 mg capsules; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Intermittent Fasting
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 21 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Renal Insufficiency
Interventions: Gefapixant; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Cerebrovascular Stroke
Interventions: Fast intervention, Active Monitoring; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pomona, California

Search by objective public record fields.

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants

OCT Guided Trans Nasal Imaging of the Small Intestine in Adults

Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects

2-A-Day Study: Twice a Day Meals Study.

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

Benazepril HCl 40 mg Tablets, Fed

Intermittent Fasting, Caloric Restriction and Body Composition in Obese Men and Women

The Effect of Intermittent Fasting on Brain Health

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Health-Kit Enabled Mobile App for Tobacco Cessation

A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum

Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers

Oatmeal Effect on N-acyl-phosphatidylethanolamines

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Zaleplon 10 mg Capsules Under Non-Fasting Conditions

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

Fast Arm Motor Skill Training in Chronic Stroke Survivors